Phio Pharmaceuticals (NASDAQ:PHIO – Get Free Report) is anticipated to release its earnings data on Monday, March 24th. Analysts expect Phio Pharmaceuticals to post earnings of ($1.23) per share for the quarter.
Phio Pharmaceuticals Stock Down 3.0 %
NASDAQ:PHIO opened at $1.29 on Friday. The stock has a market cap of $8.89 million, a P/E ratio of -0.12 and a beta of 1.28. The firm’s fifty day simple moving average is $1.93 and its 200 day simple moving average is $2.46. Phio Pharmaceuticals has a twelve month low of $1.22 and a twelve month high of $9.79.
Wall Street Analyst Weigh In
Separately, HC Wainwright reiterated a “buy” rating and issued a $4.00 price target on shares of Phio Pharmaceuticals in a report on Wednesday, February 19th.
Phio Pharmaceuticals Company Profile
Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells’ ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors.
Further Reading
- Five stocks we like better than Phio Pharmaceuticals
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Alphabet Stock Becomes a Low-Risk, High-Reward Play
- Conference Calls and Individual Investors
- Affirm Stock: Should You Buy the Dip After Walmart Setback?
- ESG Stocks, What Investors Should Know
- MarketBeat Week in Review – 03/17 – 03/21
Receive News & Ratings for Phio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
